● Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Condition: Relapsed AL Amyloidosis · Refractory AL Amyloidosis · Light Chain Amyloidosis · Sponsor: Alexion Pharmaceuticals, Inc.

PhasePhase 1/Phase 2

Planned participants91

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

This description comes directly from the study's public registry record.

Talk to the study team

Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com

Always discuss trial participation with your own doctor first.

Locations (18)

Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	San Francisco, California, United States	Recruiting
Research Site	Tampa, Florida, United States	Recruiting
Research Site	Boston, Massachusetts, United States	Recruiting
Research Site	Detroit, Michigan, United States	Recruiting
Research Site	Rochester, Minnesota, United States	Recruiting
Research Site	St Louis, Missouri, United States	Recruiting
Research Site	New York, New York, United States	Recruiting
Research Site	New York, New York, United States	Recruiting
Research Site	New York, New York, United States	Recruiting
Research Site	Cleveland, Ohio, United States	Recruiting
Research Site	Nashville, Tennessee, United States	Recruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07081646